Try Calculator
← Back to Compound Library NOOTROPICS

DSIP (Delta Sleep-Inducing Peptide)

Delta sleep-inducing peptide (DSIP) is a naturally occurring neuropeptide first isolated in 1974 by the Swiss Schoenenberger-Monnier research group from the cerebral venous blood of rabbits in an induced state of slow-wave sleep. It is a nonapeptide—a small peptide consisting of nine amino acids—with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. DSIP gained attention for its apparent ability to influence deep, slow-wave (delta) sleep rather than acting as a traditional sedative. What makes DSIP fundamentally different from conventional sleep aids is that it does not sedate. Instead of forcing drowsiness like benzodiazepines or antihistamines, DSIP appears to optimize the natural architecture of sleep. It promotes delta-wave sleep—the deepest, most restorative phase—while also influencing stress hormones, growth hormone release, and circadian rhythm regulation. DSIP has been found in both free and bound forms in the hypothalamus, limbic system, pituitary, gut, and pancreas. In the pituitary, it co-localizes with various hormones including ACTH, MSH, TSH, and melanin-concentrating hormone (MCH). It is abundant in gut secretory cells and in the pancreas where it co-localizes with glucagon. DSIP-like material has also been found in human breast milk. This wide distribution hints at a broad regulatory role far beyond sleep alone. The peptide remains experimental. It has been studied in clinical trials for insomnia, chronic pain, alcohol and opioid withdrawal, depression, and stress-related conditions, but it is not approved by any major regulatory agency. DSIP was studied clinically in the 1980s and 1990s but never completed the full regulatory approval process.

Key Characteristics

body fluids

vivo)

been identified

glucocorticoid-induced leucine zipper (GILZ)

How It Works

Sleep is not simply being unconscious. It is an active process with distinct stages, each serving different functions. Delta sleep (also called slow-wave sleep or Stage 3 NREM sleep) is the deepest phase. This is when physical restoration occurs: tissue repair, immune function, growth hormone release, and memory consolidation all happen primarily during delta sleep. DSIP appears to promote this specific phase rather than simply inducing drowsiness.

GABA and NMDA Receptor Interaction

Research suggests DSIP may interact with GABAergic systems—the same systems that benzodiazepines target—and NMDA receptors. NMDA receptors are associated with glutamate, the brain’s primary excitatory neurotransmitter, while GABA receptors mediate inhibitory neurotransmission. However, unlike drugs that directly activate these receptors and cause sedation, DSIP appears to modulate the natural sleep–wake cycle without forcing sedation. In another study, DSIP was found to stimulate acetyltransferase activity through α1 receptors in rats, suggesting additional receptor interactions beyond GABA and NMDA.

Hypothalamic–Pituitary–Adrenal (HPA) Axis Regulation

DSIP has been linked to the HPA axis, the system that controls cortisol and the stress response. Research in patients with major depressive disorder found that basal DSIP and cortisol concentrations were highly correlated and elevated compared to healthy controls. Some studies suggest DSIP can help normalize elevated cortisol levels, which is relevant for people whose sleep is disrupted by chronic stress. High cortisol at night disrupts both sleep onset and sleep quality, creating a vicious cycle that DSIP may help break.

Growth Hormone and Pituitary Function

DSIP may influence the release of growth hormone (GH) and luteinizing hormone (LH) from the pituitary. Growth hormone is released primarily during delta sleep, so enhancing deep sleep naturally supports GH secretion and recovery. Research by Iyer et al. (1988) demonstrated the effect of DSIP on the induction of slow-wave sleep and sleep-related growth hormone release. DSIP has also been shown to reduce somatostatin, a GH-inhibiting hormone, further supporting its indirect role in GH optimization.

Circadian Rhythm Modulation

Brain and plasma DSIP concentrations exhibit a marked diurnal variation, and there is a demonstrated correlation between DSIP plasma concentrations and circadian rhythm in human beings. DSIP interacts with hypothalamic pathways that coordinate sleep–wake cycles and influences serotonin and melatonin signaling. Rather than acting as a single-pathway sleep molecule, DSIP behaves as a systems-level circadian regulator.

Pain and Opioid System Modulation

DSIP has been found to have analgesic effects. In animal studies, it demonstrated a potent antinociceptive effect when administered intracerebroventricularly or intracisternally. Early research suggested these analgesic properties may operate through interaction with endogenous opioid-peptidergic systems, which also explains its effectiveness in alcohol and opioid withdrawal studies.

MAPK Cascade and GILZ Interaction

Research suggests that DSIP interacts with components of the MAPK (mitogen-activated protein kinase) cascade and is homologous to glucocorticoid-induced leucine zipper (GILZ). GILZ can be induced by dexamethasone and prevents Raf-1 activation, which inhibits phosphorylation and activation of ERK. This pathway is involved in cell proliferation, differentiation, motility, survival, and apoptosis. DSIP may affect human lens epithelial cell function via this pathway.

Mitochondrial and Antioxidant Effects

DSIP has the ability to enhance the efficiency of oxidative phosphorylation and contributes to pronounced stress-protective and antioxidant action. Research in rat models demonstrated that DSIP may help normalize stress-related metabolic fluctuations, promoting oxidative phosphorylation even under hypoxic conditions. This may have implications for stroke or myocardial ischemia, where oxygen deprivation damages tissues. DSIP analogs have also demonstrated antioxidative and detoxifying effects.

Benefits

Deeper, More Restorative Sleep

Improved Sleep Continuity

Stress Hormone Balance

Growth Hormone Support

Recovery Enhancement

Pain Modulation

Withdrawal Support

Antioxidant and Cellular Protection

lifespan study

24.1% in mice

What the Science Shows

Foundational Human Study: DSIP in Healthy Volunteers (Schneider-Helmert and Schoenenberger, 1981) This foundational study administered DSIP (25 nmol/kg) via slow intravenous infusion to six healthy volunteers. Subjects immediately reported a feeling of “sleep pressure,” and total sleep time increased by 59% within 130 minutes compared to placebo. Delayed effects on subsequent night sleep included shorter sleep onset, reduced Stage 1 sleep, and better sleep efficiency. The researchers noted that sophisticated analysis revealed no sedation in the classic pharmacological sense, suggesting DSIP sustains natural sleep functions rather than forcing them.

Double-Blind Insomnia Study (Schneider-Helmert, 1992) A double-blind study in 16 chronic insomnia patients examined DSIP (25 nmol/kg IV) administered over three consecutive afternoons. Results showed higher sleep efficiency and shorter sleep latency with DSIP compared to placebo. However, the researchers cautioned that effects were weak and suggested short-term treatment may not be of major therapeutic benefit for chronic insomnia, highlighting the importance of realistic expectations.

Intermediate-Term Insomnia Study (Schneider-Helmert, 1987) In a placebo-controlled, double-blind study of 14 chronic insomniacs, DSIP was administered for seven successive nights. Polysomnograms were obtained at baseline, during treatment, and post- treatment. Total NREM sleep time and Stage 2 sleep were increased by the peptide. The number of nocturnal awakenings, NREM sleep latency, total waking time, and waking time after sleep onset were all decreased. However, slow-wave sleep (Stages 3–4) was not significantly modified, leading the authors to conclude that sleep improvement under DSIP was of limited clinical significance.

Chronic Pain Pilot Study (Larbig et al., 1984) A pilot study investigated DSIP in seven patients with chronic pronounced pain episodes, including migraines, vasomotor headaches, chronic tinnitus, and psychogenic panic attacks. DSIP was administered intravenously on five consecutive days followed by five injections every 48–72 hours. DSIP significantly lowered pain levels in six out of seven patients. Remarkably, a simultaneous significant reduction of concomitant depressive states was also observed. The study additionally referenced earlier work showing DSIP helped with withdrawal symptoms in alcoholics and opiate addicts.

Depression and HPA Axis Study (Lesch et al., 1988) This study examined the DSIP response to corticotropin-releasing hormone (CRH) in patients with major depressive disorder. It found that basal DSIP and cortisol concentrations were highly correlated and significantly higher in depressed patients than in healthy controls. The findings supported a modulatory function of DSIP in the HPA axis and its potential significance in understanding and treating stress-related conditions.

Withdrawal Studies

Clinical research explored DSIP for alcohol and opioid withdrawal. In one trial, 97% of opiate- dependent and 87% of alcohol-dependent patients reported symptom relief with DSIP administration. These findings demonstrated the peptide’s broader effects on stress regulation and neural homeostasis beyond sleep alone.

Stress-Protective Effects (Sudakov et al., 2004)

Research published in the Annals of the New York Academy of Sciences demonstrated the stress-protective properties of DSIP sequelae. The findings supported DSIP’s role as a systems- level homeostatic modulator with pronounced stress-protective effects.

Anticarcinogenic and Geroprotective Study

In a lifespan study on mice, injecting a preparation of DSIP over the animals’ lifetime decreased total spontaneous tumor incidence 2.6-fold. The same study found geroprotective effects: DSIP slowed the age-related decline of estrous function, decreased the frequency of chromosome aberrations in bone marrow cells by 22.6%, and increased maximum lifespan by 24.1% compared to controls.

Mitochondrial Function (Khvatova et al., 2003) Research demonstrated that DSIP affects mitochondrial respiration under experimental hypoxia, enhancing the efficiency of oxidative phosphorylation. This finding has potential implications for protection against ischemic damage in stroke and cardiac events.

Key Limitations

The research on DSIP is limited by small sample sizes, varied methodologies, and age (most studies are from the 1980s and 1990s). The peptide’s very short half-life (approximately 15 minutes in vitro) due to rapid enzymatic degradation complicates dosing and may explain inconsistent results across studies. The gene encoding DSIP has never been identified, and its primary receptor target remains unresolved. Some studies showed minimal or no improvement in certain populations, and responsiveness appears dose- and timing-dependent. There is also conflicting evidence regarding its involvement in sleep patterns, with some studies showing no correlation with slow-wave sleep promotion.

Dosing Protocol

DSIP dosing is not well-established because the peptide never completed the full regulatory approval process. The following protocols are based on clinical research data and practitioner experience. Approach with appropriate caution.

Understanding the Dose Context

Clinical studies typically used weight-based dosing around 25 nmol/kg (approximately 21 mcg/kg), often administered intravenously over one to four days. In research and practitioner use, subcutaneous injection has become the standard route because it is more practical, even though bioavailability may differ from IV administration. Clinical studies used approximately 1– 2 mg total doses via IV infusion.

Standard Protocols

Protocol Dose Timing Duration Sleep optimization 100–300 mcg daily 30–60 min before bed 4–8 weeks, then assess Advanced 250–500 mcg daily 30–60 min before bed 4–8 weeks, then 2–4 sleep/recovery weeks off Clinical reference ~21 mcg/kg (25 Afternoon IV 1–7 consecutive days (IV) nmol/kg) infusion

Important Dosing Notes

would work against natural sleep patterns.

low, intermittent dosing.

complementary approach.

Draw Volumes – 5 mg Vial

Dose 2 mL Recon Units 3 mL Recon Units (2.5 mg/mL) (1.67 mg/mL) 100 mcg 0.04 mL 4 units 0.06 mL 6 units 200 mcg 0.08 mL 8 units 0.12 mL 12 units 300 mcg 0.12 mL 12 units 0.18 mL 18 units 500 mcg 0.20 mL 20 units 0.30 mL 30 units

At 200 mcg daily from a 5 mg vial: 25 doses. At 300 mcg daily: approximately 16 doses. The 3 mL reconstitution provides easier measurements for standard doses.

Reconstitution Instructions

Step 1: Remove the flip-off cap from the vial and wipe the rubber stopper with an alcohol swab. Step 2: Draw your chosen volume of bacteriostatic water (2 mL or 3 mL) into a sterile syringe. Step 3: Insert the needle through the rubber stopper at an angle. Step 4: Inject the water slowly down the inside wall of the vial to avoid foaming. Step 5: Gently swirl or roll the vial until the powder is fully dissolved. Do not shake vigorously. Step 6: The solution should be clear and colorless. If cloudy or particulate, discard. Step 7: Label the vial with the reconstitution date, concentration, and contents. Step 8: Refrigerate at 2–8°C (36–46°F). Use within 4 weeks for optimal potency.

Side Effects and Cautions

DSIP has limited safety data, though the available clinical research suggests it is well tolerated at low doses with minimal physiological or biochemical side effects.

Reported Side Effects

Safety Profile

What Remains Unknown

Key Consideration: Short Half-Life

DSIP has a very short half-life in vitro (approximately 15 minutes) due to the action of a specific aminopeptidase-like enzyme. In the body, it may be stabilized by complexing with carrier proteins, or it may exist as a component of a larger precursor molecule. This rapid degradation complicates dosing and may explain inconsistent results across studies.

Contraindications and Precautions

Avoid

additive effects)

Use with Caution

Not a Substitute For

Comparison with Other Sleep Compounds

DSIP occupies a unique position among sleep-related compounds: it promotes deep sleep without causing sedation or disrupting natural sleep architecture.

Compound Mechanism Sedation Natural Dependence Delta Sleep

Sleep

DSIP Delta sleep promotion No Supports None reported Enhances / HPA modulation Melatonin Circadian signaling Mild Supports None No direct effect Benzodiazepines Direct GABA Yes Disrupts High Suppresses activation Z-drugs GABA-A modulation Yes Disrupts Moderate Suppresses Trazodone Serotonin / histamine Yes Partially Low Minimal supports effect Glycine NMDA / No Supports None No direct thermoregulation effect Pinealon Gene expression / No Supports None reported Indirect melatonin

Melatonin helps with sleep timing but does not specifically enhance delta sleep. Sedatives force sleep but often reduce sleep quality and carry dependence risks. DSIP uniquely targets sleep depth and quality while preserving natural architecture.

DSIP vs. Melatonin

Melatonin primarily regulates sleep timing by signaling the circadian system. DSIP enhances sleep depth and quality, specifically promoting delta sleep. They work through entirely different mechanisms and can potentially complement each other: melatonin for sleep onset, DSIP for sleep depth.

DSIP vs. Pinealon

Both DSIP and Pinealon influence sleep and circadian regulation, but through different pathways. Pinealon (Glu-Asp-Arg) is a short bioregulatory peptide that acts through DNA-level gene expression modulation, particularly affecting tryptophan hydroxylase and serotonin synthesis. DSIP works through GABAergic, NMDA, and HPA axis pathways at the systems level. DSIP targets delta sleep directly, while Pinealon supports the broader circadian and neurochemical framework.

Success Tips

Fix the Basics First

DSIP is not a magic solution for poor sleep habits. If you consume caffeine late in the day, stare at screens until bedtime, or keep an irregular sleep schedule, no peptide will fully compensate. Get the fundamentals right: consistent sleep and wake times, a dark and cool bedroom, and a wind-down routine.

Consistent Timing

Take DSIP at the same time each evening, typically 30 to 60 minutes before your target bedtime. Consistency reinforces the circadian pattern you want to establish.

Track Sleep Quality

DSIP’s effects on sleep architecture may not be obvious without tracking. Consider using a sleep tracker or keeping a sleep journal. Monitor:

Start with Lower Doses

Begin with 100–200 mcg to assess your response. Some people are sensitive and respond well to lower doses. You can increase if needed, but there is no benefit to starting high—and higher doses do not necessarily improve outcomes.

Pair with Daytime Nootropics

If you use Semax or other nootropics for daytime cognitive performance, DSIP provides a complementary nighttime protocol. Better sleep enhances the cognitive benefits of daytime nootropics, and the compounds work through different mechanisms without interfering with each other.

Address Underlying Stress

DSIP works partly through stress hormone modulation. If your sleep problems are driven by chronic stress, addressing the root cause through lifestyle changes, stress management practices, or professional support will enhance DSIP’s effectiveness.

Storage and Handling

Before Reconstitution

After Reconstitution

Travel

Legal Status

United States

Europe

WADA Status

use.

Regulatory Context

DSIP was studied clinically in the 1980s and 1990s but never completed the regulatory approval process. This does not necessarily indicate it is unsafe; it means the commercial and regulatory pathway was not pursued. The peptide remains available as a research compound in most jurisdictions.

Frequently Asked Questions

How is DSIP different from melatonin? Melatonin primarily regulates sleep timing by signaling the circadian system. It tells your body when to sleep but does not directly enhance sleep quality or depth. DSIP appears to enhance the depth and quality of sleep, specifically promoting delta (deep) sleep. They work through entirely different mechanisms and can potentially complement each other. Will DSIP make me feel drugged or groggy? No. Unlike sedatives, DSIP does not cause the “drugged” feeling or next-day grogginess. Research analysis revealed no sedation in the classic pharmacological sense. DSIP supports natural sleep processes rather than forcing sedation. Most users report feeling more refreshed upon waking. How long before I notice effects? Some users notice improved sleep within the first few nights. Others find that benefits accumulate over one to two weeks. Effects are subtle, not dramatic—track your sleep quality to identify changes that might be gradual.

Can I use DSIP long-term?

Long-term safety data does not exist. Most protocols recommend cycling (4–8 weeks on, then a break) to assess whether benefits persist and to avoid potential tolerance. Some people use DSIP only during demanding periods or recovery phases.

Does DSIP increase growth hormone? Indirectly. DSIP promotes delta sleep, which is when most growth hormone is naturally released. By improving deep sleep, you naturally support GH secretion. DSIP has also been shown to reduce somatostatin, a GH-inhibiting hormone. This is different from compounds that directly stimulate GH release. Can I take DSIP with melatonin? Theoretically yes, since they work through different mechanisms. Melatonin helps with sleep- onset timing while DSIP enhances sleep depth. However, start with one compound to understand your individual response before combining. Why does DSIP have inconsistent effects across studies? DSIP has a very short half-life (approximately 15 minutes in vitro) due to rapid enzymatic degradation. In the body, it may be stabilized by carrier proteins, but this instability complicates dosing. Effects also appear to be dose- and timing-dependent, and responsiveness varies between individuals. The gene encoding DSIP has never been identified, and the primary receptor target remains unresolved. Can DSIP help with chronic pain? Clinical pilot data showed DSIP significantly lowered pain levels in six out of seven patients with migraines, vasomotor headaches, chronic tinnitus, and psychogenic pain. A simultaneous reduction in depressive symptoms was also observed. However, this evidence is preliminary and from small studies. Is DSIP the same as a sleeping pill? No. DSIP is fundamentally different from sleeping pills. Sedatives like benzodiazepines and Z- drugs force sleep by activating GABA receptors but often suppress deep sleep and REM, carry dependence risks, and cause next-day impairment. DSIP supports the body’s natural sleep architecture—specifically promoting delta sleep—without sedation, dependence, or disruption of sleep quality.

References

1. Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (delta- sleep)-inducing peptide. Proceedings of the National Academy of Sciences USA. 1977;74(3):1282–1286. 2. Schneider-Helmert D, Schoenenberger GA. Effects of DSIP in man: multifunctional psychophysiological properties besides induction of natural sleep. Neuropsychobiology. 1983;9(4):197–206. 3. Schneider-Helmert D. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: a double-blind study. Neuropsychobiology. 1992;25(1):19–23. 4. Schneider-Helmert D. DSIP in insomnia (intermediate-term study). Neuropsychobiology. 1987. 5. Larbig W, et al. Therapeutic effects of delta sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. European Neurology. 1984;23(6):657–661. 6. Lesch KP, et al. Delta sleep-inducing peptide response to human corticotropin-releasing hormone (CRH) in major depressive disorder. Biological Psychiatry. 1988;24(2):162–172. 7. Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neuroscience and Biobehavioral Reviews. 1984;8(1):83–93. 8. Pollard BJ, Pomfrett CJD. Delta sleep-inducing peptide. European Journal of Anaesthesiology. 2001;18:419–422. 9. Sudakov KV, et al. Delta-sleep-inducing peptide sequelae: stress protective effect. Annals of the New York Academy of Sciences. 2004;1018:282–287. 10. Khvatova EM, et al. Delta sleep-inducing peptide (DSIP): effects on mitochondrial respiration under experimental hypoxia. Peptides. 2003;24(2):307–311. 11. Mikhaleva II, et al. Antioxidative and detoxifying effects of analogues of delta-sleep- inducing peptide (DSIP). Bioorganicheskaia Khimiia. 2014;40(1):3–11. 12. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry. 2006. 13. Iyer KS, et al. DSIP and sleep-related growth hormone release. 1988. 14. Gimble JM, et al. Delta sleep-inducing peptide and glucocorticoid-induced leucine zipper: potential links between circadian mechanisms and obesity. Obesity Reviews. 2009. 15. Wikipedia. Delta sleep-inducing peptide. November 2025. 16. Peptide Sciences. DSIP 5mg: neuroendocrine regulation and sleep-related signaling research. 2024.

Property Support

Our Property Support services are designed to help homeowners, property managers, and businesses maintain safe, clean, and well-functioning properties year-round.

Get In Touch